Compare VanEck Rare Earth/Strategic Metals (REMX) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Rare Earth/Strategic Metals vs BIO-TECHNE Corp — how do they compare? VanEck Rare Earth/Strategic Metals trades at $61.8 (market cap $1.79B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: BIO-TECHNE Corp is far larger — about 6.4× VanEck Rare Earth/Strategic Metals's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while VanEck Rare Earth/Strategic Metals pays none. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Rare Earth/Strategic Metals for 50 Days and BIO-TECHNE Corp for 63 Days on average.
| REMX | TECH | |
|---|---|---|
Market Cap | $1.79B | $11.37B |
Volume | 1,233,740 | 3,153,511 |
Sector | Sector/Thematic | Health |
52-Week High | $109.53 | $72.61 |
52-Week Low | $60.58 | $43.31 |
Typical Hold Time | 50 Days | 63 Days |
Enterprise Value | — | $11.40B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
REMX (VanEck Rare Earth and Strategic Metals ETF) is trading at $61.88, down 2.99% with a bearish technical signal. The ETF faces selling pressure across moving averages and oscillators, though RSI readings below 23 suggest potential oversold conditions. Recent news highlights increased institutional interest from Bank of America while the rare earth sector navigates geopolitical tensions and U.S. supply chain developments.
The ETF's high volatility (~50% annualized) and China-heavy exposure present significant risks, though strategic importance of rare earth metals for defense and technology offers long-term thematic appeal. Current technical weakness contrasts with fundamental tailwinds from U.S. supply chain initiatives, creating a contested investment case requiring careful risk assessment.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Rare Earth/Strategic Metals
REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
